Meta10-19
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 1/2Active (FDA IND cleared March 2026)
Key Facts
Indication
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase
Phase 1/2
Status
Active (FDA IND cleared March 2026)
Company
About Leman Biotech
AI-enabled metabolic cancer immunotherapy company developing next-generation metabolically armored cell therapies to cure solid tumors and hematological cancers.
View full company profileAbout Leman Biotech
AI-enabled metabolic cancer immunotherapy company developing next-generation metabolically armored cell therapies to cure solid tumors and hematological cancers.
View full company profileTherapeutic Areas
Other Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) Drugs
| Drug | Company | Phase |
|---|---|---|
| TBI-1501 | Takara Bio | Phase I/II |
| Obecabtagene autoleucel (obe-cel) | Autolus Therapeutics | Phase 2 / Pivotal |